ALRN vs. ACXP, EYEN, SLGL, FBRX, UBX, ENLV, APM, SNSE, DRRX, and VIRX
Should you be buying Aileron Therapeutics stock or one of its competitors? The main competitors of Aileron Therapeutics include Acurx Pharmaceuticals (ACXP), Eyenovia (EYEN), Sol-Gel Technologies (SLGL), Forte Biosciences (FBRX), Unity Biotechnology (UBX), Enlivex Therapeutics (ENLV), Aptorum Group (APM), Sensei Biotherapeutics (SNSE), DURECT (DRRX), and Viracta Therapeutics (VIRX). These companies are all part of the "pharmaceutical preparations" industry.
Acurx Pharmaceuticals (NASDAQ:ACXP) and Aileron Therapeutics (NASDAQ:ALRN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, community ranking, media sentiment, risk, analyst recommendations, valuation and institutional ownership.
In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than Aileron Therapeutics. MarketBeat recorded 4 mentions for Acurx Pharmaceuticals and 2 mentions for Aileron Therapeutics. Aileron Therapeutics' average media sentiment score of 0.00 beat Acurx Pharmaceuticals' score of -0.50 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media.
Acurx Pharmaceuticals' return on equity of -130.32% beat Aileron Therapeutics' return on equity.
Acurx Pharmaceuticals presently has a consensus target price of $12.00, suggesting a potential upside of 479.71%. Aileron Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 280.00%. Given Aileron Therapeutics' higher possible upside, research analysts plainly believe Acurx Pharmaceuticals is more favorable than Aileron Therapeutics.
Aileron Therapeutics received 202 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 90.91% of users gave Acurx Pharmaceuticals an outperform vote while only 66.88% of users gave Aileron Therapeutics an outperform vote.
Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Aileron Therapeutics, indicating that it is currently the more affordable of the two stocks.
Acurx Pharmaceuticals has a beta of -1.9, meaning that its share price is 290% less volatile than the S&P 500. Comparatively, Aileron Therapeutics has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.
11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.9% of Aileron Therapeutics shares are owned by institutional investors. 35.3% of Acurx Pharmaceuticals shares are owned by insiders. Comparatively, 5.6% of Aileron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Acurx Pharmaceuticals beats Aileron Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Aileron Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aileron Therapeutics Competitors List
Related Companies and Tools
